Consolidation with a short course of daratumumab in patients with AL amyloidosis or light chain deposition disease
Efstathios Kastritis, Pantelis Rousakis, Ioannis V. Kostopoulos, Maria Gavriatopoulou, Foteini Theodorakakou, Despina Fotiou, Ioanna Dialoupi, Magdalini Migkou, Μαρία Ρούσσου, Nikolaos Kanellias, M.E. Tselegkidi, Evangelos Eleutherakis‐Papaiakovou, Asimina Papanikolaou, Charikleia Gakiopoulou, Erasmia Psimenou, Marylin Spyropoulou-Vlachou, Anastasia Gatou, Evangelos Terpos, Ourania Tsitsilonis, Meletios Α. Dimopoulos
Abstract
Daratumumab has major and rapid activity in AL amyloidosis with favourable toxicity. We used as a consolidation a short course of daratumumab in 25 patients with AL amyloidosis or light chain deposition disease (LCDD), who had not achieved a haematologic complete response (hemCR) after standard therapy with bortezomib, cyclophosphamide and dexamethasone (VCD). We evaluated minimal residual disease (MRD) and changes in the bone marrow (BM) microenvironment before and after consolidation using next generation flow cytometry (NGF). At the time of consolidation, 21 patients were in very good partial response (VGPR) and four in partial response (PR); all had detectable MRD. One month after consolidation completion, 8 patients (32%) achieved a hemCR, of whom 5 (20%) became also MRD negative. In the BM, we observed significant changes in B-cell precursors, naïve B-cells, T-cells, CD27+ NK & NKT cells, mast cells and erythroblasts. After a median follow-up of 25 months, none of the patients in hemCR has relapsed and all have achieved an organ response; a haematologic relapse occurred in 6/17 patients that did not achieve hemCR. In conclusion, consolidation with a short course of daratumumab can improve depth of response in patients with AL amyloidosis or LCDD and significantly affects BM environment.